As Amgen tries to get into neuroscience
anonymous Guest anonymous   Sep 02, 2016 at 02:34: PM #1 anonymous Guest As Amgen tries to get into neuroscience
anonymous Guest anonymous   Sep 02, 2016 at 07:32: PM #2 anonymous Guest anonymous said: As Amgen tries to get into neuroscience Click to expand... Amgen has always been very bad at neuroscience.
anonymous said: As Amgen tries to get into neuroscience Click to expand... Amgen has always been very bad at neuroscience.
anonymous Guest anonymous   Sep 02, 2016 at 08:37: PM #3 anonymous Guest Neuroscience leadership has always been very poor, obscure scientists with dodgy backgrounds.
anonymous Guest anonymous   Sep 02, 2016 at 09:15: PM #4 anonymous Guest Erenumab / AMG334 is a winner.
anonymous Guest anonymous   Sep 02, 2016 at 09:28: PM #5 anonymous Guest The innovation behind AMG334 is rooted in protein sciences, not neuroscience.
anonymous Guest anonymous   Sep 02, 2016 at 09:52: PM #6 anonymous Guest anonymous said: Erenumab / AMG334 is a winner. Click to expand... Just like repatha the other competitors are very similar and the differentiation will be minimal. Amgen can't play unless the drug is novel and no else is in the area.
anonymous said: Erenumab / AMG334 is a winner. Click to expand... Just like repatha the other competitors are very similar and the differentiation will be minimal. Amgen can't play unless the drug is novel and no else is in the area.